Overview

A class action lawsuit has been filed against AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) and certain of the Company’s former senior executive officers alleging violations of the federal securities laws.  The AstraZeneca class action lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired publicly traded AstraZeneca securities between February 23, 2022, and December 17, 2024, both dates inclusive (the “Class Period”).  Investors have until February 21, 2025, to seek appointment as lead plaintiff in the AsztraZeneca class action lawsuit.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.  Based in Cambridge, United Kingdom, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.  Pertinent to this action are AstraZeneca’s business activities in China.  AstraZeneca entered the Chinese market in 1993, and its Chinese headquarters are in Shanghai.

The AstraZeneca class action lawsuit alleges that Defendants, throughout the Class Period, provided materially false and/or misleading statements about the Company and failed to disclose the following adverse facts pertaining to the Company’s business, operations, and prospects, which were known to Defendants or recklessly disregarded by them.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) AstraZeneca engaged in insurance fraud in China; (2) as a result, AstraZeneca faced heightened legal exposure in China, which eventually resulted in the AstraZeneca China President being detained by Chinese law enforcement authorities; (3) as a result, AstraZeneca understated its legal risks; (4) the foregoing, once revealed, could materially harm AstraZeneca’s business activities in China; and (5) as a result, Defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

*          *          *

If you purchased or otherwise acquired publicly traded AstraZeneca securities between February 23, 2022, and December 17, 2024, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as lead plaintiff in the AstraZeneca class action lawsuit is February 21, 2025.